Piper Jaffray helps finance product development and corporate purposes
By Devika Patel
Knoxville, Tenn., April 3 - Catalyst Pharmaceutical Partners, Inc. said it priced a $25.03 million public sale of stock with a $3.75 million greenshoe. The deal was announced Wednesday.
The company will sell 11,325,000 common shares at $2.21 per share. The price per share is identical to the April 2 closing share price.
Piper Jaffray & Co. is the bookrunning manager.
Settlement is expected April 8.
Proceeds will be used for product development efforts, pre-commercialization activities and general corporate purposes.
Catalyst is a Coral Gables, Fla.-based specialty pharmaceutical company.
| Issuer: | Catalyst Pharmaceutical Partners, Inc.
|
| Issue: | Common stock
|
| Amount: | $25,028,250
|
| Greenshoe: | $3,754,238
|
| Shares: | 11,325,000
|
| Price: | $2.21
|
| Warrants: | No
|
| Bookrunner: | Piper Jaffray & Co.
|
| Co-lead manager: | Roth Capital Partners
|
| Co-manager: | H.C. Wainwright & Co., LLC
|
| Announcement date: | April 2
|
| Pricing date: | April 3
|
| Settlement date: | April 8
|
| Stock symbol: | Nasdaq: CPRX
|
| Stock price: | $2.21 at close April 2
|
| Market capitalization: | $129.95 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
